Skip to main content

Increased Cancer Risk with Autoimmune Disorders

The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.

The cohort included 8,120 AID patients from a national tertiary referral center with a follow-up of 38,726.55 patient-years.  AID diagnsoes included patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome (SS), systemic scleroderma (SSc), and idiopathic inflammatory myositis (IIM). 

The observed a total of 430 cancers (5.3%). The standardized incidence ratio (SIR) of cancer in AIDs patients (compared to general population) was :

  • Overall: 3.37
  • Idiopathic inflammatory myositis: 4.31 (higher risk of ovarian cancer)
  • RA: 3.99 (wide distribution of non-Hodgkin’s lymphoma, gynecologic, urinary tract, thyroid gland and lung cancers)
  • Systemic Sclerosis: 3.77 (increased risk of cervical uterine, lung, and breast cancers)
  • Sjogrens: 2.88 (most common  non-Hodgkin’s lymphoma)
  • SLE: 2.58 (most common: hematologic malignancies; solid tumors in the urinary bladder, corpus uteri and cervix)

Cancers in AID patients were more likely in females (female vs. male: SIR 3.59 vs. 2.77) and younger patients (age <50 vs. ≥50 years: SIR 4.88 vs. 3.04).

Cancer screening is highly appropriate in these autoimmune disorders. 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject